O12. Survival of patients with advanced EGFR-mutated NSCLC treated with EGFR TKIS in routine clinical practice

BACKGROUND: The use of epidermal growth factor receptor (EGFR) TKIs in EGFR-mutated non-small cell lung cancer (NSCLC) moved the survival boundary for these patients up to impressive 19 to 35 months, as reported in seven randomized clinical trials (RCTs). In addition, latest results of RCTs show sig...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Transl Lung Cancer Res
Huvudupphovsmän: Hitij, Nina Turnsek, Sadikov, Aleksander, Knez, Lea, Mohorcic, Katja, Jakelj, Andraz, Cufer, Tanja
Materialtyp: Artigo
Språk:Inglês
Publicerad: Pioneer Bioscience Publishing Company 2014
Ämnen:
CELCC 2014 Abstracts
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4367788/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB011
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk